Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
<p><strong>Background:</strong> Glioblastoma is the most common and aggressive primary brain tumor with extremely poor prognosis, highlighting an urgent need for developing novel treatment options. Identifying epigenetic vulnerabilities of cancer cells can provide excellen...
Main Authors: | Ozyerli-Goknar, E, Kala, EY, Aksu, AC, Bulut, I, Cingöz, A, Nizamuddin, S, Biniossek, M, Seker-Polat, F, Morova, T, Aztekin, C, Kung, SHY, Syed, H, Tuncbag, N, Gönen, M, Philpott, M, Cribbs, AP, Acilan, C, Lack, NA, Onder, TT, Timmers, HTM, Bagci-Onder, T |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
BioMed Central
2023
|
Registos relacionados
-
Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
Por: Ezgi Ozyerli-Goknar, et al.
Publicado em: (2023-11-01) -
EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
Por: Yedier-Bayram, O, et al.
Publicado em: (2022) -
The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma
Por: Ozyerli-Goknar, E, et al.
Publicado em: (2019) -
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
Por: Saraç, H, et al.
Publicado em: (2019) -
Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma
Por: Filiz Senbabaoglu, et al.
Publicado em: (2020-12-01)